MK-2206

Generic Name: MK-2206

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₁N_₅O

CAS Number: 1032349-93-1

Unique Ingredient Identifier: 51HZG6MP1K

Clinical Trials

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase 2

Terminated

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: MK2206

First Posted Date: 2011-11-08

Last Posted Date: 2014-07-10

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 22

Registration Number: NCT01466868

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Centre Henri Mondor, Créteil, France
🇫🇷
CHRU, Lille, France

and more 10 locations

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Recurrent Gallbladder Carcinoma
Advanced Adult Hepatocellular Carcinoma
Stage IV Gallbladder Cancer
Localized Non-Resectable Adult Liver Carcinoma
Recurrent Adult Liver Carcinoma
Stage IV Distal Bile Duct Cancer
Unresectable Extrahepatic Bile Duct Carcinoma
Unresectable Gallbladder Carcinoma

Interventions: Drug: Akt Inhibitor MK2206
Other: Diagnostic Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2011-08-30

Last Posted Date: 2016-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT01425879

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

and more 5 locations

MK-2206 in Recurrent Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Recurrent Nasopharyngeal Carcinoma

Interventions: Drug: MK-2206

First Posted Date: 2011-06-09

Last Posted Date: 2017-01-13

Lead Sponsor: Chinese University of Hong Kong

Target Recruit Count: 12

Registration Number: NCT01370070

Locations: 🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: Akt Inhibitor MK2206
Drug: Bendamustine Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Rituximab

First Posted Date: 2011-06-09

Last Posted Date: 2017-09-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT01369849

Locations: 🇺🇸
Metro-Minnesota NCI Community Oncology Research Program, Saint Louis Park, Minnesota, United States
🇺🇸
Minnesota Oncology and Hematology PA-Woodbury, Woodbury, Minnesota, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

and more 41 locations

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Recurrent Squamous Cell Carcinoma of the Nasopharynx
Stage IV Squamous Cell Carcinoma of the Nasopharynx

Interventions: Drug: Akt inhibitor MK2206

First Posted Date: 2011-05-09

Last Posted Date: 2017-12-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT01349933

Locations: 🇨🇳
Chinese University of Hong Kong-Prince of Wales Hospital, Shatin, Hong Kong, China
🇸🇬
Johns Hopkins Singapore International Medical Centre, Singapore, Singapore
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 5 locations

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Invasive Breast Carcinoma
Recurrent Breast Carcinoma
Estrogen Receptor Positive
Stage IV Breast Cancer AJCC v6 and v7

Interventions: Drug: Akt Inhibitor MK2206
Drug: Anastrozole
Drug: Fulvestrant
Other: Laboratory Biomarker Analysis

First Posted Date: 2011-04-28

Last Posted Date: 2018-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT01344031

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: MK-2206 + AZD6244

First Posted Date: 2011-04-12

Last Posted Date: 2015-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT01333475

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Phase 2

Terminated

Conditions: Stage IB Breast Cancer
Stage IIB Breast Cancer
Estrogen Receptor Positive
Progesterone Receptor Negative
Stage IIA Breast Cancer
Estrogen Receptor Negative
HER2/Neu Negative
Stage IIIC Breast Cancer
Triple-Negative Breast Carcinoma
HER2/Neu Positive

Interventions: Drug: Akt Inhibitor MK2206
Procedure: Therapeutic Conventional Surgery
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2011-03-21

Last Posted Date: 2017-08-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT01319539

Locations: 🇺🇸
Albert Einstein College of Medicine, The Bronx, New York, United States
🇺🇸
Montefiore Medical Center - Moses Campus, The Bronx, New York, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Phase 2

Completed

Conditions: Endometrial Adenosquamous Carcinoma
Recurrent Uterine Corpus Carcinoma
Endometrial Serous Adenocarcinoma
Endometrial Adenocarcinoma
Endometrial Clear Cell Adenocarcinoma

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis

First Posted Date: 2011-03-03

Last Posted Date: 2022-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT01307631

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 4 locations

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Carcinoma, Small Cell Lung
Carcinoma, Thymic

Interventions: Drug: Erlotinib
Drug: AZD6244
Drug: MK-2206
Drug: Lapatinib
Drug: Sunitinib
Procedure: Molecular Profiling

First Posted Date: 2011-03-01

Last Posted Date: 2024-10-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 647

Registration Number: NCT01306045

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy